Breast Cancer

Bireociclib plus fulvestrant significantly improved progression-free survival and response rates in advanced HR-positive breast cancer, with manageable safety and consistent benefits across high-risk subgroups.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.

Rural US patients with breast cancer face higher advanced-stage diagnoses, with Black, Hispanic, uninsured patients and those in Southern regions at greatest risk.

A new meta-analysis links menopausal hormone therapy to higher breast cancer risk with estrogen-progestin therapy, while estrogen-only therapy may lower risk.

Risk-based mammography tailors screening to breast cancer risk, reducing false positives and preventing more deaths than age-based screening.

Sequencing CDK4/6i to the second line rather than the first appears to produce equivalent survival for most patients with meaningfully less treatment burden.

A study of 1.5 million patients suggests that ACA Medicaid expansion reduces breast cancer deaths, especially advanced cases—yet racial and income gaps persist.

Sarah M. Lima, PhD, MPH, on how historical redlining continues to shape breast cancer survival disparities through treatment access and innovation.

Ateequllah Hayat, PhD, discusses epigenetic rewiring, biomarkers, and emerging strategies to overcome lapatinib resistance in HER2+ breast cancer.

Standard double reading did not perform as well as artificial intelligence for looking at catching cancer and reduced the rate of breast cancer diagnosis by 12%.

Genetic and metabolic differences may increase aggressive early breast cancer risk in Latin American women with obesity, notes William Audeh, MD, MS.

Smart pill bottles may boost adherence to oral breast cancer therapies through daily reminders and tracking, though cost and technology barriers remain, says Steven Manobianco, MD.

Findings from SABCS genetic differences between Latin American and non-Hispanic White women with breast cancer and h

Amrita Basu, PhD, says AI can transform health care by streamlining data, enhancing decision-making, and unlocking insights to improve patient outcomes.

Molecular ESR1 changes may signal symptomatic progression before imaging in metastatic breast cancer, supporting camizestrant for improved quality of life.

New therapies and individualized care plans for menopausal women highlighted the most-read 2025 SABCS coverage.

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

A novel phase 1 trial explores the safety and efficacy of targeted radiotherapy for leptomeningeal metastases in breast cancer patients.

The FDA approved trastuzumab deruxtecan plus pertuzumab for first-line HER2-positive metastatic breast cancer after DESTINY-Breast09 showed major PFS gains.

Phase 1 data presented by Andrew Brenner, MD, PhD, showed RNL-186 improved survival, reduced symptoms, and demonstrated strong safety in patients with leptomeningeal metastases.

Our top breast cancer stories in 2025 covered FDA approvals, new and failed therapies, screening gaps, and policy factors shaping treatment access and outcomes.

Erika Hamilton, MD, reports early trial data showing DB-1305/BNT325, a TROP2-targeted ADC, produced encouraging responses in heavily pretreated TNBC patients.

A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.

Men's breast cancer awareness is crucial as it often goes unrecognized, leading to advanced stages at diagnosis, Michael Hassett, MD, explains.

Michael Hassett, MD, explains the evolving landscape of HER2-positive breast cancer treatment and the role of CDK inhibition in personalized therapy strategies.